Shandong Pharmaceutical Companies Grab Over $1 Billion of Antithrombotic Drugs for The First Imitation, Original Research Drugs Soared 5527%

On May 27, Shandong New Era Pharmaceuticals submitted a generic marketing application for Class 4 edoxaban tosylate tablets. At present, there is no domestic generic drug of this product on the market. Hainan Simcere Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, and Nanjing Hailing Pharmaceutical of Yangzijiang Pharmaceutical Group have applied for production, all of which are under review and approval. the more intense.

Edoxaban is a selective factor Xa inhibitor developed by Daiichi Sankyo. It was first approved for venous thromboembolism in Japan in 2011, and has since been approved for multiple new indications. Global sales in 2021 amounted to 189.4 billion yen (about 1.5 billion US dollars).

The original research product was approved to enter the domestic market at the end of 2018. According to the data of Minet, in 2021, the sales of the original research product will be carried out in the terminals of urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) in China. The growth rate is as high as 5527.67%, and the market potential should not be underestimated. From the perspective of channel structure, it is rapidly expanding to county-level public hospitals, urban community centers and township health centers.

At present, the xaban products listed on the domestic market include apixaban tablets, rivaroxaban tablets and edoxaban tosylate tablets, of which apixaban tablets and rivaroxaban tablets have been domestically imitated and obtained In recent years, edoxaban tosylate tablets have also attracted a number of domestic star pharmaceutical companies to compete for the first imitation. Shandong New Era Pharmaceuticals is the fourth to report production, and we will wait and see who will eventually be the first imitation.

Shandong New Times Pharmaceutical is also actively developing anti-thrombotic drugs. Earlier, the company has won atragaban injection, rivaroxaban tablets, enoxaparin sodium injection, and tirofiban hydrochloride for injection. Varaxaban tablets won the bid for the fifth batch of national mining.